Interventions for fatigue in Parkinson's disease: A systematic review and meta-analysis

Movement Disorders

Volumn 29, Issue 13, 2014, Pages 1675-1678

  Franssen, Marloes ^a   Winward, Charlotte ^b   Collett, Johnny ^a   Wade, Derick ^c   Dawes, Helen ^a  

^a OXFORD BROOKES UNIVERSITY   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c OXFORD CENTRE FOR ENABLEMENT   (United Kingdom)

Author keywords

Amphetamines; Dopamine; Fatigue; Meta analysis; Parkinson's disease

Indexed keywords

COMPLICATION; FATIGUE; HUMAN; META ANALYSIS; PARKINSON DISEASE;

FATIGUE; HUMANS; PARKINSON DISEASE;

EID: 84911204582     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26030     Document Type: Article

References (26)

1. Herlofson K, Larsen JP. The influence of fatigue on health-related quality of life in patients with Parkinson's disease. Acta Neurol Scand 2003;107:1-6.
2. Winward C, Sackley C, Meek C, et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Mov Disord 2012;27:143-146.
3. Miwa H, Miwa T. Fatigue in patients with Parkinson's disease: impact on quality of life. Intern Med 2011;50:1553-1558.
4. Herlofson K, Larsen JP. Measuring fatigue in patients with Parkinson's disease: the Fatigue Severity Scale. Eur J Neurol 2002;9:595-600.
5. Havlikova E, van Dijk JP, Rosenberger J, et al. Fatigue in Parkinson's disease is not related to excessive sleepiness or quality of sleep. J Neurol Sci 2008;270:107-113.
6. Abe K, Takanashi M, Yanagihara T. Fatigue in patients with Parkinson's disease. Behav Neurol 2000;12:103-106.
7. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S42-S80.
8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
9. Abe K, Takanashi M, Yanagihara T, Sakoda S. Pergolide mesilate may improve fatigue in patients with Parkinson's disease. Behav Neurol 2001;13:117-121.
10. Leentjens AF, Scholtissen B, Vreeling FW, Verhey FR. The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach. Neuropsychopharmacology 2006;31:1009-1015.
11. Lou JS, Dimitrova DM, Park BS, et al. Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol 2009;32:305-310.
12. Mendonca DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 2007;22:2070-2076.
13. Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005;76:1636-1639.
14. Ondo WG, Shinawi L, Davidson A, Lai D. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat Disord 2011;17:156-159.
15. Schifitto G, Friedman JH, Oakes D, et al. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology 2008;71:481-485.
16. Tyne HL, Taylor J, Baker GA, Steiger MJ. Modafinil for Parkinson's disease fatigue. J Neurol 2010;257:452-456.
17. Stocchi F. Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease. Eur J Neurol 2014;21:357-360.
18. Drijgers RL, Verhey FRJ, Tissingh G, Van Domburg PHMF, Aalten P, Leentjens AFG. The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate. J Neurol Sci 2012;320:121-126.
19. Rios Romenets S, Creti L, Fichten C, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease: a randomized study. Parkinsonism Relat Disord 2013;19:670-675.
20. Ghahari S, Leigh Packer T, Passmore AE. Effectiveness of an online fatigue self-management programme for people with chronic neurological conditions: a randomized controlled trial. Clin Rehabil 2010;24:727-744.
21. Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012;79:651-658.
22. Friedman JH, Alves G, Hagell P, et al. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord 2010;25:805-822.
23. Friedman JH, Brown RG, Comella C, et al. Fatigue in Parkinson's disease: a review. Mov Disord 2007;22:297-308.
24. Friedman JH, Alves G, Hagell P, et al. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord 2010;25:805-822.
25. Ray Chaudhuri K, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord 2013;19:660-665.
26. Adler CH, Thorpy MJ. Sleep issues in Parkinson's disease. Neurology 2005;64(12 Suppl 3):S12-S20.